Internal mammary sentinel lymph node biopsy in clinical practice

Area of Science:

• Oncology
• Surgical Oncology
• Breast Cancer Research

Background:

• Internal mammary sentinel lymph node biopsy (IM-SLNB) is a validated technique for breast cancer staging.
• Current treatment decisions for internal mammary lymph nodes (IMLN) often rely on axillary lymph node (ALN) status.

Discussion:

• Relying solely on ALN status for IMLN treatment can lead to overtreatment (unnecessary radiation) or undertreatment (missed adjuvant therapy).
• This approach may not accurately reflect the true status of internal mammary lymph nodes in all patients.

Key Insights:

• IM-SLNB provides accurate staging information for internal mammary lymph nodes.
• Patients with confirmed drainage to IMLNs benefit from IM-SLNB irrespective of their ALN status.
• Direct assessment via IM-SLNB improves personalized treatment planning for breast cancer.

Outlook:

• Further research should focus on integrating IM-SLNB findings directly into treatment algorithms.
• This technique holds promise for optimizing radiation therapy and systemic treatment strategies.
• Wider adoption of IM-SLNB could enhance patient outcomes and reduce treatment-related morbidity.